An Open-label, Multi-center, Phase IV Roll-over Study in Patients With ALK Positive Malignancies Who Have Completed a Novartis-sponsored Ceritinib (LDK378) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Ceritinib
Phase of Trial: Phase IV
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Ceritinib (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 11 Mar 2018 Planned primary completion date changed from 14 Dec 2020 to 29 Mar 2018.
- 09 Aug 2016 Planned End Date changed from 1 Nov 2020 to 1 Dec 2020.
- 09 Aug 2016 Planned primary completion date changed from 1 Nov 2020 to 1 Dec 2020.